Tags

Type your tag names separated by a space and hit enter

Malaria chemoprophylaxis: what do the travelers choose, and how does pretravel consultation influence their final decision.
Am J Trop Med Hyg. 2007 Dec; 77(6):1010-4.AJ

Abstract

Three different drugs (mefloquine, atovaquone/proguanil, doxycycline) are recommended for malaria chemoprophylaxis, each with approximately the same efficacy but various adverse event profiles, regimens, and prices. We investigated which medication the travelers would have chosen on the basis of written evidence-based information and the impact that pretravel consultation had on their decision. A prospective study was performed in a travel clinic and private practice, and 1073 travelers were included; 45% chose mefloquine (Lariam or Mephaquine), 21% atovaquone/proguanil (Malarone), 18% doxycycline (Supracycline), 5% "no prophylaxis," and 11% "do not know." Lariam was principally chosen because of prior experience (38%), Mephaquine because of low price (34%), and doxycycline and Malarone because of the profile of adverse events (55% and 43%, respectively). Based on objective written information, travelers most frequently chose mefloquine for chemoprophylaxis. This suggests that evidence-based information weighs more heavily than negative publicity. Taking into account the perspective of the user should improve appropriateness of the pretravel advice.

Authors+Show Affiliations

Travel Clinic, Department of Ambulatory Care and Community Medicine, Switzerland. nicolas.senn@gmail.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18165513

Citation

Senn, Nicolas, et al. "Malaria Chemoprophylaxis: what Do the Travelers Choose, and How Does Pretravel Consultation Influence Their Final Decision." The American Journal of Tropical Medicine and Hygiene, vol. 77, no. 6, 2007, pp. 1010-4.
Senn N, D'Acremont V, Landry P, et al. Malaria chemoprophylaxis: what do the travelers choose, and how does pretravel consultation influence their final decision. Am J Trop Med Hyg. 2007;77(6):1010-4.
Senn, N., D'Acremont, V., Landry, P., & Genton, B. (2007). Malaria chemoprophylaxis: what do the travelers choose, and how does pretravel consultation influence their final decision. The American Journal of Tropical Medicine and Hygiene, 77(6), 1010-4.
Senn N, et al. Malaria Chemoprophylaxis: what Do the Travelers Choose, and How Does Pretravel Consultation Influence Their Final Decision. Am J Trop Med Hyg. 2007;77(6):1010-4. PubMed PMID: 18165513.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Malaria chemoprophylaxis: what do the travelers choose, and how does pretravel consultation influence their final decision. AU - Senn,Nicolas, AU - D'Acremont,Valérie, AU - Landry,Pierre, AU - Genton,Blaise, PY - 2008/1/1/pubmed PY - 2008/2/15/medline PY - 2008/1/1/entrez SP - 1010 EP - 4 JF - The American journal of tropical medicine and hygiene JO - Am J Trop Med Hyg VL - 77 IS - 6 N2 - Three different drugs (mefloquine, atovaquone/proguanil, doxycycline) are recommended for malaria chemoprophylaxis, each with approximately the same efficacy but various adverse event profiles, regimens, and prices. We investigated which medication the travelers would have chosen on the basis of written evidence-based information and the impact that pretravel consultation had on their decision. A prospective study was performed in a travel clinic and private practice, and 1073 travelers were included; 45% chose mefloquine (Lariam or Mephaquine), 21% atovaquone/proguanil (Malarone), 18% doxycycline (Supracycline), 5% "no prophylaxis," and 11% "do not know." Lariam was principally chosen because of prior experience (38%), Mephaquine because of low price (34%), and doxycycline and Malarone because of the profile of adverse events (55% and 43%, respectively). Based on objective written information, travelers most frequently chose mefloquine for chemoprophylaxis. This suggests that evidence-based information weighs more heavily than negative publicity. Taking into account the perspective of the user should improve appropriateness of the pretravel advice. SN - 0002-9637 UR - https://www.unboundmedicine.com/medline/citation/18165513/Malaria_chemoprophylaxis:_what_do_the_travelers_choose_and_how_does_pretravel_consultation_influence_their_final_decision_ L2 - https://ClinicalTrials.gov/search/term=18165513 [PUBMED-IDS] DB - PRIME DP - Unbound Medicine ER -